cabozantinib

This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the

Latest news

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

access cabozantinib earlier in their treatment pathway.”.
Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
FDA’s year-end approvals take annual tally to 46

Exelixis got the nod from the US regulator for Cabometyx (cabozantinib) as a first-line treatment for advanced renal cell carcinoma, giving the drug a boost against rival Sutent (sunitinib) from ... therapy. Analysts at Leerink have suggested the new
Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication. Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half ... Data showed cabozantinib provided a ‘statistically
NICE gives green light to Ipsen's Cabometyx

To date nearly 300 patients in the UK have benefited from cabozantinib through this Ipsen initiative, whilst the NICE process took place. ... We are delighted that now any eligible patient in the UK can benefit from cabozantinib.

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Associate Director: £75, 000-90, 000

Account Director: Competitive Salary Offered

Global Business Development Director – Health Education: excellent commission

Engagement Expert, Healthcare Brand Communications, London: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager: Competitive Salary Offered

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Business Director: Competitive Salary Offered

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Medical Writer: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Account Director development role to Business Director, H...: Excellent package

Account Director, Medical Education: Salary TBC

Medical Writer: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Account Manager / Account Director: Competative

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...